A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: testing (1000), conducting tests (149)

Rituximab SC (8 weekly) Ver 1

Description
Chemotherapy Protocol LYMPHOMA RITUXIMAB SC (8 weekly) Regimen Lymphoma – Rituximab SC (8 weekly) Indication Maintenance single agent therapy in previously untreated
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Rituximab-SC-8-weekly-Ver-1.pdf

Rituximab SC (12 weekly) Ver1

Description
Chemotherapy Protocol LYMPHOMA RITUXIMAB SC (12 weekly) Regimen Lymphoma – Rituximab SC (12 weekly) Indication Maintenance single agent therapy in relapsed / refractory
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Rituximab-SC-12-weekly-Ver1.pdf

Rituximab (8 weekly)

Description
Chemotherapy Protocol LYMPHOMA RITUXIMAB (8 Weekly) Regimen Lymphoma – Rituximab (8 weekly) Indication Non-Hodgkin’s Lymphoma as first-line maintenance therapy
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Rituximab-8-weekly.pdf

FC PO (5 day)-Cyclophosphamide-Fludarabine PO 5 day Ver 1.1

Description
Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-FLUDARABINE ORAL 5 DAY (FC PO 5 day) Regimen Lymphoma – FC PO (5 day)-Cyclophosphamide-Fludarabine PO
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/FC-PO-5-day-Cyclophosphamide-Fludarabine-PO-5-day-Ver-1.1.pdf

Bexarotene

Description
Chemotherapy Protocol Cutaneous T-cell Lymphoma BEXAROTENE Regimen • Cutaneous T-cell Lymphoma - Bexarotene Indication • Bexarotene is indicated for the treatment of
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Bexarotene.pdf

Regorafenib

Description
Chemotherapy Protocol Gastro-Intestinal Stromal Tumour Regorafenib Regimen • GIST – Regorafenib Indication • Regorafenib is recommended for histologically confirmed metastatic or unresectable gastronintestinal
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Sarcoma/Regorafenib.pdf

Regorafenib

Description
Chemotherapy Protocol Hepatocellular Cancer Regorafenib Regimen • Hepatocellular – Regorafenib Indication • Regorafenib is recommended as an option for treating advanced unresectable hepatocellular carcinoma
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Hepatobiliary/Regorafenib.pdf

Carboplatin AUC2-RT

Description
Chemotherapy Protocol HEAD AND NECK CANCER CARBOPLATIN (AUC2)-RADIOTHERAPY Regimen • Head and Neck Cancer – Carboplatin(AUC2)-Radiotherapy Indication • SCC of the
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Headandneckcancer/Carboplatin-AUC2RT.pdf

Carboplatin AUC1.5+RT

Description
Chemotherapy Protocol HEAD AND NECK CANCER CARBOPLATIN (AUC1.5)-RADIOTHERAPY Regimen • Head and Neck Cancer – Carboplatin(AUC1.5)-Radiotherapy Indication • SCC
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Headandneckcancer/Carboplatin-AUC1.5RT.pdf

Ponatinib

Description
Chemotherapy Protocol Chronic Myeloid Leukaemia Ponatinib All licensed indications are not funded therefore an application for funding is required before prescribing
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CML/Ponatinib.pdf
341 to 350 of 517
Previous … 33 34 35 36 37 … Next